78 results about "MS multiple sclerosis" patented technology

Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising the prodrugs of methyl hydrogen fumarate, and methods of using the prodrugs of methyl hydrogen fumarate and the pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.

A dual action recumbent exercise cycle which provides upper body, lower body and cardiovascular conditioning with emphasis directed toward the needs of obese individuals as well as individuals with equilibrium issues such as Parkinson's Disease, Multiple Sclerosis and Stroke. The apparatus includes a multi-configurable seat which is horizontally displaced from the foot pedal and handlebar assemblies. A vaned wheel rotatably mounted on the frame and arranged to absorb energy by movement of the broad surfaces of the vanes against the surrounding body of air. A derailleur mechanism is provided for additional options of resistance intensity. Rotation of the wheel is effected through a pair of foot pedals and connected chain and sprocket/hub mechanism and/or through a pair of handlebar assemblies. The handlebar assemblies each include a pivotal spring housing mechanism which enables the handlebars to be both retractable and variable in their positioning to the user. Each handlebar assembly is pivotally connected to the frame and is also connected to a respective eccentric through a crank ring rotatably mounted on that eccentric and a drive bar connected to both the crank ring and the handlebar stem. The two eccentrics are arranged 180 degrees out of phase and are connected to the foot pedals so as to rotate in response to both the pivotal movement of the handlebar stems and the circular movement of the foot pedals. As the eccentrics are drivably connected to the vaned wheel, that vaned wheel is caused to rotate in response to rotation of the eccentrics.

The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.

Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample.

An alkannin derivative as immuno-suppressive agent and its metallic complex compound with a chemical constitution formulas III and IV disclosed in the specification, wherein in formula III, R is C1-6 saturated, unsaturated and aromatic acyl, in formula IV, R is hydrogen, C1-6 saturated, unsaturated and aromatic acyl, M is metallic Cu, Ca, Zn. The present invention realizes immunological suppression effect, thus can be used for treating diseases relating to human body autoimmune including chronic infectious arthritis, scleredema, lupus erythematosus, HIV infection and malignant tumor.

The invention discloses an application of a hepatocyte growth factor (HGF) and a medulla desmohemoblast stem cell (MSC)-containing conditioned medium (MSC-CM) in preparation of medicines for treating multiple sclerosis (MS). The research result shows that in a cord sheath oligodendrocyte glycoprotein 35-55 peptide fragments (MOG35-55) induced MS animal model EAE, human MSC paracrine substance-containing MSC-CM is provided to reduce the EAE functional defect, and the growth of oligodendrocyte and neuron can be promoted when the functional cells are injured, wherein the HGF which is released by MSC performs the main effect; the effect provided to HGF is similar with MSC-CM, and the growth and movement of oligodendrocyte and neuron can be stimulated, the cord sheath restoration capability can be enhanced, the pathology load of MS animal model (EAE) can be minimized, the disease recovery function can be promoted, and short HGF treatment on the EAE model is provided for continuously guiding the disease function improvement. According to the invention, the application scope of HGF and MSC-CM can be widened, an effective medicine is provided for clinical treatment of MS, and the deep exploitation of a novel high efficiency MS treatment medicine can be realized simultaneously.

The invention belongs to the technical field of chemical medicines and relates to a biaryl urea carboxylic acid derivative or a salt of the compound of formula I, as well as a preparation method, a medicinal composition and application of the compound in preparing medicines for treating diseases related to RORgamma t. Study results show that the compound can effectively inhibit RORgamma t protein receptors, so that differentiation of Th17 cells can be regulated and controlled, generation of IL-17 can be inhibited, treatment medicines for inflammation related diseases mediated by RORgamma t can be further prepared, and inflammation related diseases such as disseminated sclerosis, rheumatoid arthritis, collagen-induced arthritis, psoriasis, inflammatory bowel diseases, encephalomyelitis, clone diseases, asthma and cancer can be treated. The formula I is as shown in the specification.

The disclosure relates to the treatment, diagnosis and/or prevention of multiple sclerosis (MS) by using an immunodominant protein or peptide. More particular the invention relates to the field of antigen specific immunotherapies, such as the induction of tolerance.

The present invention provides a method for treating a disease or disorder responsive to inhibition of nuclear factor-KB transcription factor, comprising administering a sulfonylaminocarbonyl derivative or a pharmaceutically acceptable salt thereof to a patient in need of treatment. The methods of the invention are useful, for example, in the treatment of rheumatoid arthritis, osteoarthritis, autoimmune diseases, psoriasis, asthma, cardiovascular disease, acute coronary syndrome, congestive heart failure, Alzheimer's disease, multiple Cirrhosis, cancer, type 2 diabetes, metabolic syndrome X, or inflammatory bowel disease.

Markers useful for determining multiple sclerosis activity in a human subject are provided, along with kits for measuring quantitative expression values of the markers. Also provided are computer systems and software embodiments of predictive models for scoring and determining multiple sclerosis activity in human subjects based on the quantitative expression values of the markers.

The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.

4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is also disclosed.

The invention discloses a method for establishing a non-human primate autoimmune cerebrospinal meningitis model and the application of the model. The specific technical scheme comprises the following steps; a machin is selected as the non-human primate experimental animals; MOG34-56(100Mug/ml) is prepared into an emulsion (MOG CFA=1; 1); after the experimental machin is anesthetized, the machin is intradermally injected with 1ml of prepared emulsion at 10 injection points; on the seventh day after the first injection, an MOG-CFA emulsion is prepared by use of the same method, and the second immune injection is performed at the same dosage and by use of the same method; the experimental autoimmune cerebrospinal meningitis model established by use of the method has the clinical characters of remission-relapse, and can be widely used to the related field of disseminated sclerosis diseases. Compared with the existing rhesus method and model, the method and the model also have the characteristics of short induction period, low cost, rich monkey resources and the like, and also have the application value which cannot be realized by rodent models.

The invention relates to a composition and a method conducive to acquiring follicular regulatory T cells in vitro and an application of the composition. The invention proves that differentiation and number proliferation of in-vitro Tfr (follicular regulatory T cells) can be effectively induced by the aid of irritation of TGF (transforming growth factor)-beta, IL (interleukin)-2, anti-CD3 antibodies, anti-CD28 antibodies and baicalin, and expression of Foxp3 in the Tfr is facilitated. The Tfr cells amplified by the method can be used for treating autoimmune diseases and chronic inflammatory diseases, the autoimmune diseases include lupus erythematosus, dermatomyositis, vasculitides, sicca syndrome, scleroderma, rheumatoid arthritis, ankylosing spondylitis, disseminated sclerosis and autoimmune hepatitis, and the chronic inflammatory diseases include diabetes, coronary heart diseases, hyperlipemia, eczema, vitiligos, atopic dermatitis, lichen planus and the like.

The present invention relates to a method of diagnosing primary progressive multiple sclerosis (PPMS) in a patient suspected of having PPMS. Further, the present invention relates to a method of determining the course of PPMS in a patient having PPMS. Furthermore, the present invention relates to a method of determining the severity of PPMS in a patient suspected of having PPMS. It also relates to the use of at least one metabolite for diagnosing PPMS in a patient suspected of having PPMS, for determining the course of PPMS in a patient having PPMS, or for determining the severity of PPMS in a patient suspected of having PPMS. In addition, it relates to a kit for diagnosing PPMS in a patient suspected of having PPMS, for determining the course of PPMS in a patient having PPMS, or for determining the severity of PPMS in a patient suspected of having PPMS.

The present invention relates to the use of a liquid aqueous solution of edaravone in the treatment of an oxidative stress-mediated neurodegenerative disorder in a human patient, said treatment comprising at least once daily oral administration of the liquid edaravone solution to the human patient, to provide a daily dose of 40-120 mg edaravone during an uninterrupted period of at least 10 days. Examples of oxidative stress-mediated neurodegenerative disorders that can be treated in this way include amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), cerebral amyloid angiopathy (CAA), Alzheimer's disease and Parkinson's disease.

The present invention provides compositions and methods of use thereof for treating or ameliorating multiple sclerosis (MS) by administering a depot formulation comprising 40 mg glatiramer acetate intramuscularly to the MS patient.